Last reviewed · How we verify

Standard Opioid

Prisma Health-Upstate · FDA-approved active Small molecule

Standard opioids bind to opioid receptors in the central and peripheral nervous system to reduce pain perception and produce analgesia.

Standard opioids bind to opioid receptors in the central and peripheral nervous system to reduce pain perception and produce analgesia. Used for Moderate to severe acute pain, Chronic pain (cancer-related and non-cancer pain).

At a glance

Generic nameStandard Opioid
SponsorPrisma Health-Upstate
Drug classOpioid analgesic
TargetMu opioid receptor (primary); delta and kappa opioid receptors (secondary)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Opioids are agonists at mu, delta, and kappa opioid receptors, with mu-receptor activation being the primary mechanism for analgesia and euphoria. By binding to these G-protein coupled receptors, opioids inhibit neurotransmitter release and hyperpolarize neurons, reducing pain signal transmission. They also modulate descending pain pathways in the brainstem and spinal cord.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: